V. Le Gros

发表

Insights into severe asthma control as assessed by guidelines, pulmonologist, patient, and partner

D. Vervloet, M. Molimard, V. Le Gros, 2010, The Journal of asthma : official journal of the Association for the Care of Asthma.

Impact of Patient-Related Factors on Asthma Control

M. Molimard, V. Le Gros, 2008, The Journal of asthma : official journal of the Association for the Care of Asthma.

A proof-of-concept, randomized, controlled trial of omalizumab in patients with severe, difficult-to-control, nonatopic asthma.

M. Humbert, A. Didier, P. Berger, 2012, Chest.

Omalizumab decreases nonspecific airway hyperresponsiveness in vitro

R. Marthan, P. Berger, J. Tunon-de-lara, 2007, Allergy.

FEV1 reversibility does not adequately predict effect of formoterol via Aerolizer® in chronic obstructive pulmonary disease

D. Benhamou, A. Cuvelier, J. Muir, 2004, International journal of clinical practice.

Long- and short-acting beta2 adrenoceptor agonists: interactions in human contracted bronchi.

E. Naline, B. Bégaud, C. Advenier, 1998, The European respiratory journal.

Faster onset of bronchodilation with formoterol than with salmeterol in patients with stable, moderate to severe COPD: results of a randomized, double-blind clinical study.

G. D. Cioppa, N. Siafakas, R. Pistelli, 2002, Canadian respiratory journal.

Rapid onset of bronchodilation in COPD: a placebo-controlled study comparing formoterol (Foradil Aerolizer) with salbutamol (Ventodisk).

D. Benhamou, A. Cuvelier, J. Muir, 2001, Respiratory medicine.

Effectiveness of omalizumab (Xolair) in the first patients treated in real-life practice in France.

A. Didier, F. de Blay, M. Molimard, 2008, Respiratory medicine.

Omalizumab reduces oral corticosteroid use in patients with severe allergic asthma: real-life data.

J. Thirlwell, R. Buhl, R. Maykut, 2010, Respiratory medicine.

Comparison between formoterol 12 microg b.i.d. and on-demand salbutamol in moderate persistent asthma.

M. Molimard, V. Le Gros, I. Bourdeix, 2001, Respiratory medicine.

Observational study in severe asthmatic patients after discontinuation of omalizumab for good asthma control.

M. Molimard, V. Le Gros, I. Bourdeix, 2012, Respiratory medicine.

ALLERGY Net: Effectiveness of omalizumab in monozygotic twin sisters with severe allergic asthma

J. Just, V. Le Gros, F. Sahraoui, 2007, Allergy.

Omalizumab effectiveness in patients with severe allergic asthma according to blood eosinophil count: the STELLAIR study

M. Humbert, J. Just, M. Molimard, 2018, European Respiratory Journal.

Effect of omalizumab in health care workers with occupational latex allergy.

V. Le Gros, I. Bourdeix, F. Leynadier, 2004, The Journal of allergy and clinical immunology.

Effects of formoterol and salmeterol on resting inspiratory capacity in COPD patients with poor FEV1 reversibility

N. Siafakas, Demosthenes Bouros, G. Della Cioppa, 2004, Current medical research and opinion.

Prevalence and associated factors of oropharyngeal side effects in users of inhaled corticosteroids in a real-life setting.

M. Molimard, V. Le Gros, I. Bourdeix, 2010, Journal of aerosol medicine and pulmonary drug delivery.

Influence of local radiotherapy on penetration of fluconazole into human saliva

B. Frachet, M. Tod, O. Petitjean, 1993, Antimicrobial Agents and Chemotherapy.

Clinical efficacy with formoterol in the absence of a response to salmeterol: a review.

G. Della Cioppa, V. Le Gros, J. Kottakis, 2001, International journal of clinical practice.

Lung and skin hypersensitivity to 5-aminosalicylic acid.

V. Le Gros, G. Lesur, N. Brion, 1991, BMJ.

Pharmacokinetics and bactericidal activities of one 800-milligram dose versus two 400-milligram doses of intravenously administered pefloxacin in healthy volunteers

M. Tod, O. Petitjean, K. Louchahi, 1993, Antimicrobial Agents and Chemotherapy.

Magnetopneumography: a general review.

J. Pozzi, F. Liot, V Le Gros, 1989, The European respiratory journal.

[Pulmonary and bronchial kinetics of cefuroxime after a single 500 mg intramuscular injection].

R. Farinotti, V. Le Gros, J. Régnard, 1992, Pathologie-biologie.

[Pituitary metastasis of a small cell bronchial carcinoma responsible for diabetes insipidus and disclosed by corticosteroid therapy].

S. Poiraudeau, V. Le Gros, J. Tourani, 1987, Revue des maladies respiratoires.

Efficacy and safety of indacaterol in patients with chronic obstructive pulmonary disease aged over 65 years: A pooled analysis.

P. Girodet, W. Cao, V. Le Gros, 2017, Respiratory medicine.

Total reversibility testing as indicator of the clinical efficacy of formoterol in COPD.

M. Molimard, V. Le Gros, I. Bourdeix, 2005, Respiratory medicine.

[Estimation of pulmonary dust load using magnetic pneumography].

J. Pozzi, F. Liot, P. Berthaud, 1988, Revue des maladies respiratoires.

Omalizumab-induced decrease of FcξRI expression in patients with severe allergic asthma.

M. Humbert, A. Didier, P. Chanez, 2010, Respiratory medicine.

A population pharmacokinetic study of alminoprofen penetration into synovial fluid

M. Tod, O. Petitjean, K. Louchahi, 1995, Biopharmaceutics & drug disposition.

THERAPEUTIC EQUIVALENCE OF DICLOFENAC SUSTAINED‐RELEASED 75 MG TABLETS AND DICLOFENAC ENTERIC‐COATED 50 MG TABLETS IN THE TREATMENT OF PAINFUL OSTEOARTHRITIS

X. le Loët, R. Dreiser, V. Le Gros, 1997, International journal of clinical practice.

Insights into severe asthma control as assessed by guidelines, pulmonologist, patient, and partner

D. Vervloet, M. Molimard, V. Le Gros, 2010, Journal of Asthma.